Greenfire Resources Ltd (GFR) reports significant production and reserve growth, while addressing strategic transitions and operational challenges.

Results from multiple clinical trials showed that Tagrisso demonstrated survival benefits in EGFR-mutated non-small cell lung ...

New study results presented at the European Lung Cancer Congress (ELCC) 2025, 26 to 29 March, demonstrate the role of AstraZeneca’s Tagrisso (osimertinib), as monotherapy and as the backbone for novel ...

CHICAGO -- For people with heart failure (HF), the long-presumed benefits of fluid restriction did not pan out in the ...

New study results presented at the European Lung Cancer Congress (ELCC) 2025, March 26 to 29, demonstrate the role of AstraZeneca's TAGRISSO® (osimertinib), as monotherapy and as the backbone for ...

Professor Virginia Harrison, EGFR Positive UK, said ... Stage III EGFRm NSCLC (hazard ratio [HR] 0.67; 95% confidence interval [CI] 0.40, 1.14, maturity 31%). Median OS was 58.8 months ...

In LAURA Phase III trial, TAGRISSO continues to demonstrate improved overall survival trend in unresectable, Stage III setting SAVANNAH and ORCHARD Phase II trials show the addition of savolitinib ...

The first-line combination of amivantamab-vmjw plus lazertinib extended OS compared with osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer, according to data from the ...

67, and 70 Tracy Morgan says he's OK, food poisoning caused incident at Knicks-Heat game 'Has Done a Lot of Difficult and Significant Things': Elon Musk Says These Current and Former CEOs Are the ...

The Jammu and Kashmir government has said that the implementation of the Rs 67.62 crore e-Office project in the Union Territory has been carried out by the Jammu and Kashmir e-Governance Agency ...

Biotech Pharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", Stock Code: 6990.HK) announced its audited consolidated results for the year ended December 31, 2024 (the "Reporting ...